Blog

Pfizer Doses First Patient Using Investigational Mini-Dystrophin … – Business Wire (press release)


Business Wire (press release)

Pfizer Doses First Patient Using Investigational Mini-Dystrophin …
Business Wire (press release)
NEW YORK–(BUSINESS WIRE)–Pfizer Inc. has initiated a Phase 1b clinical trial for its mini-dystrophin gene therapy candidate, PF-06939926, in boys with Duchenne muscular dystrophy (DMD). The first boy received an infusion of the mini-dystrophin gene
Pfizer Begins Clinical Trial With Mini-dystrophin Gene Therapy CandidateNasdaq


Pfizer (PFE) Commences Phase 1b Clinical Trial for Investigational …StreetInsider.com
First Duchenne Patient Dosed in Pfizer's Mini-Dystrophin StudyRare Disease Report

all 1 news articles »

2018-04-12 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.